Slide 1: Cingulate Therapeutics
Cingulate Therapeutics Developing next-generation therapeutics where standard-of-care treatments result in suboptimal outcomes 40 - 2022 V7 /
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than stat
Slide 3: Next-Generation Medications in Billion-Dollar Markets
Next-Generation Medications in Billion-Dollar Markets Immediate Release Film Coat Third eon Release amet Layers Second Release See the PTR™ Platform in Action *Symphony Data. 12-months rolling through Jun 2022 Cingulate.com
Slide 4: Pipeline of Next-Generation Medications in Billion-Dollar Markets
Pipeline of Next-Generation Medications in Billion-Dollar Markets Anxiety Insomnia Migraine Depression Hypothyroidism Bipolar Disorder Oral Oncology Medicines Parkinson’s Disease Psychosis Cardiovascular Disorders Alzheimer's Disease Xerostomia (dry mouth) Pain (Non-Opioid)
Slide 5: Market Dynamics in ADHD & Anxiety
Market Dynamics in ADHD & Anxiety ADHD Anxiety ¢ $18Bn US market ¢ $5Bn US market ¢ Stimulants dominate (90%+) ¢ Buspirone is #1 non- * Top 4 ADHD meds generic at CING benzodiazepine treatment launch * Potential for breakthrough approval PBM rebates going away * PBM rebate offer to improve access Ci
Slide 6: Catalysts Into 2023
Catalysts Into 2023 4Q 2022 Zp2023 ADHD > Food Effect Clinical Study Report > Onset / Efficacy Trial > Complete CTx-1301 CTx-1301 > Initiate CTx-1301 Adult Data Pivotal Phase 3 CTx-1302 Onset / Duration Efficacy Trial > Initiate Pivotal Phase 3 in > — CTx-1302 IND Adolescents and Children > — CTx-21
Slide 7: First and Only ADHD Medication to Overcome All Unmet Needs
$18 Billion’ US ADHD Market Dominated by Stimulants FIRST and ONLY ADHD Medication to Overcome All Unmet Needs Precision Timed Release™ (PTR™) Platform Unlocks the Possibility for ‘True’ Once-daily, Multi-dose Tablets Fast Onset of Action Eliminate Need for ‘Booster/Recovery’ Meds Eliminate Rebound/
Slide 8: Targeting Treatment of ADHD - $18Bn US Market Opportunity
Targeting Treatment of ADHD - $18Bn US Market Opportunity 17 Million US ADHD Patients 11M Adults & 6M Children/Adolescents Estimated annual incremental costs of $143 to $266 billion in the United States Stimulants 91% of US Market Earn ~ 30% less and 10% less likely to be $15.3Bn! employed aE Methyl
Slide 9: ADHD Market Currently Dominated by Stimulant Products
ADHD Market Currently Dominated by 4 Stimulant Products ADHD 1 1 ayy ATTRIBUTES MET NEEDS Vyvanse® 2007 2 hours 12 hours 1% [ Not Adderall® XR 2001 fi 10 Y% hours jours Available Deas $11.6B Concerta® 2000 2 hours 10 hours Available 76% Market Nata Not Share ($)? Focalin® XR 2005 30 mins 11% hours v
Slide 10: Recent Launches Lack Meaningful Clinical Innovation
Recent Launches Lack Meaningful Clinical Innovation ADHD BRANDS ATTRIBUTES! MET NEEDS Quillivant / Chew® XR 60 mins 8 hours Mydayis® 2or4hrs 16+ hours Potentially Adzenys® ER/ODT 60 mins 8-9 hours Cotempla® XR/ODT 60 mins 10-12 hours Aptensio® XR 60 mins 9 hours Evekeo® / ODT 60 mins 10 hours Dynave
Slide 11: The Cingulate Solution for ADHD Patients & Providers
The Cingulate Solution for ADHD Patients & Providers
Slide 12: Nine Significant Points of Differentiation
Nine Significant Points of Differentiation NO ADHD product available today PTR™ technology affords our product candidates combines all unmet needs the following potential advantages over currently available ADHD treatments v Provide ‘Entire Active-Day' Efficacy V Reduce abuse / diversion by eliminat
Slide 13: One Product Overcomes All Unmet Needs
One Product Overcomes All Unmet Needs 7am Noon 3pm 7am Noon 3pm 4000 3500 40000 3000 35000 2500 CTx-1301 6.25-mg 30000 CTx-1301 50-mg wee —®— Focalin XR 5-mg woe AY —® Focalin XR 40-mg 1500 20000 1000 15000 soo j —— Extended Efficacy 10000 | 000 0 5 10 15 20 23 30 45000 OTS-TO :al a!qns +— Extended
Slide 14: CTx-1301 Demonstrated Significantly Lower Adverse Events
CTx-1301 Demonstrated Significantly Lower Adverse Events Focalin XR CTx-1301 Focalin XR CTx-1301 All All 5 mg 6.25 mg 40 mg 50 mg CTx-1301 Focalin XR (n=41) (n=39) (n=43) (n=42) (n=42) (n=44) Treatment Emergent Adverse 7 (17.1%) 4 (10.3%) 22 (51.2%) 14 (33.3%) 17 (40.5%) 25 (56.8%) Events Mild 7 (17
Slide 15: CTx-1301 Clinical and Regulatory Timeline
Z MASTERY ® CTx-1301 Clinical and Regulatory Timeline 2022 2023 2024 2025 Q CLINICAL PHASE 3 PHASE | aa Sroodil Adult Dose- PHASE 3 Effect Optimization Pediatric / Adolescent PHASE 4 Study Efficacy and Safety Fixed-Dose, Placebo- Clinical Program n=26 Study to Evaluate Controlled Study - Onset and D
Slide 16: Commercialization to Drive Revenue
Commercialization to Drive Revenue Changing dynamics in ADHD Maximize Access for Patients and Providers commercial landscape * — Clinical, Practical, and Societal Story: * — Ability to dominate share of voice * Efficacy and Tolerability o Concerta, Adderall XR, Focalin XR are all * One versus Two Pr
Slide 17: The Cingulate Solution for Anxiety
amt CINGULATE’ The Cingulate Solution for
Slide 18: CTx-2103 — Buspirone HCl for the Treatment of Anxiety
CTx-2103 — Buspirone HCl for the Treatment of Anxiety Next-Generation Buspirone designed to Improve Patient Outcomes Single Dose Buspirone 10 mg- Immediate Release ° s 10 hours 20 as Treatment D: A single tablet releasing 10 mg buspirone HCL (commercially available) immediately Cc. 30 CTx-2103 Trimo
Slide 19: Exclusivity: IP, Agreements, and Trade Secrets
Exclusivity: IP, Agreements, and Trade Secrets Intellectual property rights expected to provide exclusivity through 2035 at a minimum C Oralogik™ Erosion Barrier Layer + Five (5) patents granted (US & Global) expiry dates ranging from 2031 to 2035, * One (1) OralogiK™ patent pending (US, Europe) + T
Slide 20: Cingulate Mission
Cingulate Mission Develop... Shape market acceptance, and... Prepare to commercialize next-generation drug candidates... Where currently prescribed standard-of-care treatments result in suboptimal outcomes for all stakeholders Achievement Drives Shareholder and Team Member Value
Slide 21: Thank You
CINGULATE’ Thank You